Evolution of B12 Vitamin Blood Level in Patients with Myeloma, Lymphocytic Leukemia and Myeloblastic Leukemia in Latvia

  • Anna Tutane (Speaker)
  • Didzis Gavars (Co-author)
  • Agris Auce (Co-author)
  • Eriks Tauckels (Co-author)
  • Ilze Lindenberga (Co-author)
  • Dmitrijs Perminovs (Co-author)

Activity: Talk or presentation types › Poster presentation

Description

B12 blood level in patients with myeloma (C90 - International Classification of Diseases (ICD-10)), lymphocytic leukemia (C91) and myeloblastic leukemia (C92) were studied prior and after the diagnosis. . Studies of patient clinical histories yielded few patients with B12 tests. Study of B12 dynamics from clinical histories was deemed resource consuming. There were 7433 patients with diagnosis C90-92 in the clinical test data collected by E. Gulbis laboratory (EGL) over years 2004-2022. From these 7433 patients 1386 had one B12 test, two- 548, three and more- 864 patients. There are on average 107, 189 and 91 confirmed cases of C90, C91 and C92 per annum in Latvia. EGL data set has 30% more C90-92 patients, most probably due to suspected but later unconfirmed diagnosis. . Anonymized patient data for 7451 patients with C90-C92 diagnosis for the period of 10 years before and after the first diagnosis were studied. The strongest time dependency of B12 blood level changes was observed for C92 diagnosis where within approximately 3 years prior to diagnosis there were more patients with high and very high B12 level than those with B12 level within the reference interval. The B12 fluctuation for C92 patients was expected because in myeloblastic leukemia there is overproduction of cells from myeloid hemopoietic progenitor which includes granulocytes, and they produce B12 binding molecules transcobalamins. C90 and C91 patient data also showed B12 level changes around the diagnosis date although the effect was considerably smaller. . In silica analysis of B12 tests of C90, C91 and C92 patients over years 2004-2022 showed very strong B12 blood level change prior to diagnosis date for C92 and considerably smaller but still clearly visible change for C91 and C90 patients. The changes of B12 level after diagnosis were also observed.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content